Subject: REVISIONS to PARTICIPATING DRUG COMPANY list for MEDICAID DRUG REBATE PROGRAM

Banner Date October 06, 2023 through October 31. 2023

Cycle: 15, 16 and 17

Provider types: 07, 08, 09, 24, & 31

REVISIONS to PARTICIPATING DRUG COMPANY list for MEDICAID DRUG REBATE PROGRAM

For a drug product to be compensable through the Medical Assistance (MA) Program, the company (labeler) that markets the product must participate in the Federal Medicaid Drug Rebate Program.

The below revisions to the list, unless otherwise indicated, are effective October 1, 2023. Terminations and additions apply only to those National Drug Codes (NDCs) beginning with the five-digit labeler code indicated, and not to other NDCs that may be marketed by that company under a different labeler code.

NEW and REINSTATED LABELERS

SHORLA PHARMA LTD (81927)
ORPHALAN (81802)
BAUSCH & LOMB AMERICAS INC. (82260)
TOLMAR, INC. (69087)

GAMIDA CELL INC. (73441)

ALEXZA PHARMACEUTICALS, INC. (51097)

GENMAB US, INC. (82705)

REATA PHARMACEUTICALS, INC. (73179)

KRYSTAL BIOTECH, INC. (82194)

BRAEBURN, INC. (58284)

LIFSA DRUGS LLC (72336)

RECKITT BENCKISER, INC. (63824)

ACER THERAPEUTICS (72542)

BIOCON BIOLOGICS INC (83257)

TERMINATED LABELERS, MANDATORY AND VOLUNTARY

BAUDAX BIO, INC. (71518)

GLASSHOUSE PHARMACEUTICALS LLC (71428)

PHARMICS INC. (00813)

NABRIVA THERAPEUTICS US, INC. (72000)

LOXO ONCOLOGY, INC. (71777)

PERSION PHARMACEUTICALS, LLC. (65224)

CURRAX PHARMACEUTICALS LLC (60258)

NALPROPION PHARMACEUTICALS (51267) CURRAX PHARMACEUTICALS, LLC. (44183) CURRAX PHARMACEUTICALS, LLC. (42847) CAPELLON PHARMACEUTICALS, LTD. (64543) APNAR PHARMA LP (24689)